Founded in 1998 through a partnership with the U.S. government to supply an anthrax vaccine, Emergent BioSolutions develops, manufactures and delivers medical countermeasures and other protective products for public-health emergencies. The company has spent more than 25 years preparing governments and communities for biological threats, while also expanding access to naloxone for opioid-overdose response. Emergent also operates four North American manufacturing facilities and partners with biopharma innovators on complex development and manufacturing work.
Drug Supply Chain Security Act (DSCSA) Compliance
Compliance program
Emergent BioSolutionsFounded in 1998 to supply the U.S. government with anthrax vaccine, Emergent BioSolutions develops and manufactures medical countermeasures and other protective products for biological threats and opioid overdose emergencies. The company also operates as a strategic manufacturing partner, using specialized containment capabilities across four North American facilities to help biopharma companies, governments and nonprofits develop and make complex biological products. Its commercial portfolio includes NARCAN® Nasal Spray alongside preparedness products for threats such as anthrax, smallpox and botulism.ROCKVILLE, MD
Emergent BioSolutionsEmergent BioSolutions is a public health company that develops and manufactures protective medicines and medical countermeasures for opioid overdose emergencies and biological threats. Founded in 1998, it began by partnering with the U.S. government to supply an anthrax vaccine and now operates manufacturing facilities across the United States and Canada, alongside research and development and commercial product operations.325412PLYMOUTH MEETING, PA
BioFactura, IncFounded in Frederick in 2004, BioFactura develops and manufactures biosimilars, biodefense medical countermeasures, and other biologic medicines using its patented StableFast biomanufacturing platform. The clinical-stage company has advanced programs for a smallpox therapeutic and a proposed ustekinumab biosimilar, while its Capitol Biologics division provides development and early-phase clinical manufacturing support to emerging biotech firms and government agencies.FREDERICK, MD
SIGA Technologies, IncSIGA Technologies develops medicines for emerging infectious diseases, with its core product TPOXX serving as the first U.S. FDA-approved antiviral treatment specifically indicated for smallpox. The company’s work centers on preparing governments and public-health partners for outbreaks, while its development operations in Corvallis support studies of additional TPOXX uses and formulations. SIGA reports 50 employees, products sold in more than 30 countries, and more than $1 billion in cumulative government procurement orders.NEW YORK, NY